



announced last month that it
would invest £1.5 million in a new
centre to develop stem-cell
treatments for diabetes and
diseases of the brain.The
government-funded Medical
Research Council announced its
support for the new centre. Within
five years, patients with otherwise
incurable diseases could be
involved in testing new and
revolutionary treatments. But the
announcement is clouded by
another bill going through
parliament that aims to create new
legal controls over the use of
human tissues in research which
has sent alarm bells ringing
throughout the research
community. The proposed bill
arises from the revelations that
organs were taken  from dead
babies without parental consent at
two major children’s hospitals in
the UK which caused public
outrage.
However, the use of human
embryo stem cells in research was
backed by free votes in
Parliament, two rounds of public
consultation and a commission of
inquiry. But many think it is an
ethical step too far.
Although now authorized in
Britain, such research remains
legally difficult in the US, with
President George Bush opposing
it. Professor Roger Pedersen, one
of the leaders in the field, left
California to take advantage of
freedom to research on stem cells
in the UK.
Colin Blakemore, chief
executive of the MRC, said: “Stem
cell science offers enormous hope
for the future treatment of many
life-threatening illnesses.”
But the scientific challenge —
and the moral argument — has
centred on the use of human
embryo stem cells, either taken
from embryos left over from
fertility treatment, or created by
the kind of cloning techniques that
led to Dolly the sheep. A Korean
team announced the first cloned
human embryo in February. And a
University of Newcastle team
could be the first to get
permission to begin so-called
‘therapeutic cloning’ in Britain.
The Human Fertilisation and
Embryology Authority, which
oversees such research, met last
month to consider the application
but has decided to seek further
expert opinion before giving a
decision on the case. 
The government has proposed
changes to the forthcoming
human tissues bill which will make
it easier for researchers to work
with material obtained from living
patients. But the MRC is still
unhappy about proposals that
researchers should not have
access to the identity of donors of
tissue material which could
hamper medical research. With
ethical committee’s approval they
believe some information could be
of benefit to the tissue donor, for
example in the discovery of
antibiotic resistance for
prescribing practice. “It’s vital that
the bill both protects the rights of
patients and ensures that medical
research to benefit the future
health of those patients and their
families is able to continue,” says
Blakemore.
Pedersen’s new MRC
Cambridge Centre for Stem Cell
Biology and Medicine will
eventually cost £16.5 million. It will
be backed by the Juvenile
Diabetes Research Foundation
and other charities as well as
government funds. Its first
challenge will be to understand
what Pedersen calls ‘stemness’ —
the mysterious ability of embryo
stem cells to to become blood,
muscle, fat, bone, nerves, teeth,
hair and skin etc.
Juvenile diabetes and
Parkinson’s are the centre’s first
disease targets. This is because
they could be treated by injections
of purified stem cells of just one
type.
“We are intent upon starting
human trials at the earliest
possible date. This requires that
we understand the basic
properties of stem cells and that is
the purpose of this programme,”
Pedersen said.
Stem cell boost
Britain is publicly and privately
backing stem-cell research but
worries continue about the legal
framework scientists face in
undergoing such work, writes
Nigel Williams.
Swings and roundabouts: Stem-cell research in Britain has received a boost but
worries remain about the potential impact of a new bill to control access to human
tissues for research. (Picture: Science Photo Library.)
